Valve-in-valve transcatheter aortic valve replacement (ViV-TAVR) has emerged in recent years as a novel alternative approach to conventional Redo surgical aortic valve replacement (Redo-SAVR) resulting in an increasing trend toward implantation of biological valves at primary surgical aortic valve replacement (SAVR), even in younger patients.
← all excerpts
Failure of Surgical Aortic Valve Prostheses: An Analysis of Heart Team Decisions and Postoperative Outcomes.
1
—
—